Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Large Decrease in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 5,400 shares, a drop of 50.9% from the February 13th total of 11,000 shares. Based on an average trading volume of 9,900 shares, the days-to-cover ratio is currently 0.5 days.

Santen Pharmaceutical Price Performance

Shares of OTCMKTS SNPHY traded up $0.30 during midday trading on Friday, reaching $9.83. 3,213 shares of the stock were exchanged, compared to its average volume of 10,992. The firm has a 50-day simple moving average of $9.66 and a two-hundred day simple moving average of $10.86. Santen Pharmaceutical has a twelve month low of $8.65 and a twelve month high of $13.00.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.